Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an announcement.
Paradigm Biopharmaceuticals Limited has applied for quotation on the ASX of 6,864,326 new fully paid ordinary shares, with an issue date of 8 April 2026. The new securities arise from the exercise or conversion of options or other convertible securities, modestly expanding the company’s listed share base and potentially strengthening its capital position for ongoing operations.
The application confirms Paradigm’s compliance with ASX Listing Rules for the new share quotation and provides updated disclosure of its capital structure under the PAR ticker. While no additional operational details were disclosed, the incremental issuance may influence existing shareholders through dilution while supporting the company’s flexibility in funding future activities.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian biotechnology company listed on the ASX under the code PAR. The company operates in the biopharmaceuticals industry, focusing on the development and commercialisation of therapeutic products, though this filing centres on its capital markets activity rather than specific drugs or pipelines.
Average Trading Volume: 988,145
Technical Sentiment Signal: Sell
Current Market Cap: A$115.7M
For a thorough assessment of PAR stock, go to TipRanks’ Stock Analysis page.